TMEM144

Across TCGA pan-cancer cohorts, TMEM144 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TMEM144 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher TMEM144 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM144 expression acts as an unfavorable survival marker.

MESO, GBM, and LIHC are the cancer types where TMEM144 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	II,III,IV	0.071	0.572	<.001	24	view →
GBM	OS	Median	All	0.026	0.416	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	II,III,IV	0.206	0.612	.037	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.586	0.872	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TMEM144–MESO (OS)

Open the MESO breakdown →